BioMe™ provides essential research infrastructure and genotype-phenotype datasets for multi-disciplinary, programmatic research grants. Our faculty members lead active federal grants–all funded by the National Institutes of Health.
The Charles Bronfman Institute for Personalized Medicine
NIH Funding Programs
As part of this innovative consortium, we are currently leveraging our expertise in electronic medical records, genomics, and biomarker development to develop and validate novel biomarkers to better stratify and predict disease progression. Learn more about the consortium
With the BioMe™ cohort as a research focus, our faculty assembled multi-disciplinary research teams and succeeded in joining the U01 collaborative consortium eMERGE network. Learn more about our initiative
We aim to identify the genes that underlie the differences in disease burden between populations. We will use data from the BioMe™ Biobank and focus on cardiometabolic diseases, including type 2 diabetes, cardiovascular disease, chronic kidney disease, obesity, and blood lipids, among others. Learn more about this research
We are studying the effects and challenges of incorporating genetic risk information in clinical care for patients of African ancestry with high blood pressure who are at risk for chronic kidney disease. Learn more about The GUARDD Study: Genetic testing to Understand and Address Renal Disease Disparities